10.1210/jc.2017-02591

Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma

Abstract

Context Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce. Objective To assess the efficacy of mitotane in advanced ACC in a contemporary setting and to identify predictive factors. Design and Setting Multicenter cohort study of three German referral centers. Patients One hundred twenty-seven patients with advanced ACC treated with mitotane monotherapy. Outcome Measures Response Evaluation Criteria in Solid Tumors evaluation, progression-free survival (PFS) and overall survival (OS) by Kaplan-Meier method, and predictive factors by Cox regression. Results Twenty-six patients (20.5%) experienced objective response, including three with complete remission. Overall, median PFS was 4.1 months (range 1.0 to 73) and median OS 18.5 months (range 1.3 to 220). Multivariate analysis indicated two main predictive factors: low tumor burden (180 days). Patients who achieved mitotane levels >14 mg/L had significantly longer OS (HR 0.42; P = 0.003). Conclusions At 20.5% the objective response rate was slightly lower than previously reported. However, >20% of patients experienced long-term disease control at >1 year. In general, patients with late diagnosis of advanced disease and low tumor burden might especially benefit from mitotane monotherapy, whereas patients with early advanced disease and high tumor burden are probably better candidates for combined therapy of mitotane and cytotoxic drugs

Similar works

Full text

ZORAProvided a free PDF (195.62 KB)

152278oai:www.zora.uzh.ch:152278
Last time updated on July 6, 2018

This paper was published in ZORA.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.